Mayer Davidson to Cardiovascular Diseases
This is a "connection" page, showing publications Mayer Davidson has written about Cardiovascular Diseases.
Connection Strength
2.609
-
Davidson MB. The Role of Prediabetes in the Metabolic Syndrome: Guilt by Association. Metab Syndr Relat Disord. 2023 05; 21(4):197-204.
Score: 0.582
-
Davidson MB. Historical review of the diagnosis of prediabetes/intermediate hyperglycemia: Case for the international criteria. Diabetes Res Clin Pract. 2022 Mar; 185:109219.
Score: 0.537
-
Davidson MB. The "Cost-Effective" beneficial effect of pioglitazone on cardiovascular disease. Diabetes Res Clin Pract. 2020 07; 165:108223.
Score: 0.477
-
Davidson MB, Pan D. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract. 2018 Jan; 135:102-110.
Score: 0.400
-
Echeverry D, Dike M, Jovanovic L, Wollitzer AO, Westphal S, Mudaliar S, Washington C, Davidson MB. Efforts to improve subsequent treatment of cardiovascular risk factors in older patients with diabetes hospitalized for a cardiac event. Am J Manag Care. 2005 Dec; 11(12):758-64.
Score: 0.175
-
Davidson MB. Glycemia and risk for cardiovascular disease. Ann Intern Med. 2005 Feb 01; 142(3):227; author reply 227-8.
Score: 0.165
-
Davidson MB. Is treatment of insulin resistance beneficial independent of glycemia? Diabetes Care. 2003 Nov; 26(11):3184-6.
Score: 0.151
-
Davidson MB. Metformin Should Not Be Used to Treat Prediabetes. Diabetes Care. 2020 09; 43(9):1983-1987.
Score: 0.121